Brigatinib: clinical trials recruiting now
3
Recruiting trials
10
Conditions studied
0
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Brigatinib appears in the FDA drug-label database. Marketed as Alunbrig.
- Drug class
- Kinase Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Tyrosine Kinase Inhibitors; Cytochrome P450 3A Inducers (as stated on the FDA label)
FDA-approved use
ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 )
Phase breakdown
Phase 2 1
Not applicable 2
Conditions being studied
Recruiting trials involving Brigatinib
- ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
- Using Tumor Models to Determine Treatments
Common questions
Is Brigatinib FDA-approved?
Yes, marketed as Alunbrig.
How many recruiting trials involve Brigatinib?
3 recruiting trials across 10 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.